$ALXN Form 8-K

0
442

Form 8-K for ALEXION PHARMACEUTICALS INC


5-Jan-2017

Results of Operations and Financial Condition, Financial Statements a

Item 2.02 Results of Operations and Financial Condition.
On January 4, 2017, Alexion Pharmaceuticals, Inc. issued a press release including its anticipated revenue and earnings per share for the fiscal year ended December 31, 2016. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.The attached press release contains both U.S. Generally Accepted Accounting Principles, or GAAP, and non-GAAP financial measures. The non-GAAP financial measures exclude the impact of share-based compensation expense, fair value adjustment of inventory acquired, amortization of purchased intangible assets, changes in fair value of contingent consideration, acquisition-related costs, restructuring expenses, upfront and milestone payments related to licenses and collaborations, and adjustments to income tax expense. Reconciliations between non-GAAP and GAAP financial measures are included in the press release set forth as Exhibit 99.1 furnished to this Form 8-K. Alexion’s management utilizes non-GAAP financial information to provide a useful measure of comparative operating performance of Alexion. The non-GAAP financial measures are supplemental to and not a substitute for, measures of financial performance prepared in accordance with GAAP.

 

Item 9.01. Financial Statements and Exhibits.(d) Exhibits.

99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on January 4, 2017.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here